Benitec Biopharma Inc. financial data

Symbol
BNTC on Nasdaq
Industry
Pharmaceutical Preparations
Location
3940 Trust Way, Hayward, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 369 % +2.5%
Debt-to-equity 37.2 % -10.9%
Return On Equity -175 % +31.5%
Return On Assets -128 % +29.2%
Operating Margin -22.6K % +62.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.37M shares -66.5%
Common Stock, Shares, Outstanding 2.72M shares -90.3%
Entity Public Float 4.76M USD -77.8%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 2.62M shares +59%
Weighted Average Number of Shares Outstanding, Diluted 2.62M shares +59%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Research and Development Expense 15.3M USD +19.7%
General and Administrative Expense 6.32M USD -3.66%
Operating Income (Loss) -21.5M USD -11.5%
Nonoperating Income (Expense) -200K USD +71.4%
Net Income (Loss) Attributable to Parent -21.7M USD -8.63%
Earnings Per Share, Basic -7.17 USD/shares +85.7%
Earnings Per Share, Diluted -7.17 USD/shares +85.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.1M USD +115%
Other Assets, Current 157K USD -79.7%
Assets, Current 14.4M USD +94.3%
Property, Plant and Equipment, Net 204K USD +92.5%
Operating Lease, Right-of-Use Asset 335K USD -43.1%
Other Assets, Noncurrent 69K USD -34.3%
Assets 15M USD +82.5%
Employee-related Liabilities, Current 517K USD +20.5%
Liabilities, Current 3.44M USD +9.01%
Operating Lease, Liability, Noncurrent 62K USD -82.5%
Liabilities 3.5M USD -0.23%
Accumulated Other Comprehensive Income (Loss), Net of Tax -835K USD +2.11%
Retained Earnings (Accumulated Deficit) -185M USD -13.3%
Stockholders' Equity Attributable to Parent 11.5M USD +144%
Liabilities and Equity 15M USD +82.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.58M USD -13.2%
Net Cash Provided by (Used in) Financing Activities 27.9M USD +74.3%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 160M shares 0%
Common Stock, Shares, Issued 2.72M shares -90.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.4M USD +87.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.2M USD +116%
Deferred Tax Assets, Valuation Allowance 21.9M USD +22%
Deferred Tax Assets, Gross 22.3M USD +21.7%
Operating Lease, Liability 354K USD -43.2%
Depreciation 19K USD -54.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.7M USD -12.2%
Lessee, Operating Lease, Liability, to be Paid 365K USD -44.4%
Property, Plant and Equipment, Gross 1.58M USD +12.9%
Operating Lease, Liability, Current 292K USD +8.55%
Lessee, Operating Lease, Liability, to be Paid, Year Two 291K USD -3.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 74K USD -74.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11K USD -67.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 62K USD -18.4%
Deferred Tax Assets, Operating Loss Carryforwards 18.4M USD +6%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 68K USD +9.68%
Depreciation, Depletion and Amortization 82K USD -32.2%
Share-based Payment Arrangement, Expense 503K USD +2.03%